Literature DB >> 19576214

Reduction in endothelial tip cell filopodia corresponds to reduced intravitreous but not intraretinal vascularization in a model of ROP.

Steven Budd1, Grace Byfield, David Martiniuk, Pete Geisen, Mary Elizabeth Hartnett.   

Abstract

To determine the effect of a vascular endothelial growth factor receptor 2 tyrosine kinase (VEGFR2) inhibitor on intravitreous neovascularization (IVNV), endothelial tip cell filopodia, and intraretinal vascularization in a rat model of retinopathy of prematurity (ROP). Within 4h of birth, newborn Sprague-Dawley rat pups and their mothers were cycled between 50% and 10% oxygen daily until postnatal day (p)12. Pups were given intravitreous injections of VEGFR2 inhibitor, SU5416, or control (dimethyl sulfoxide, DMSO) and returned to oxygen cycling until p14, then placed into room air. Intravitreous neovascularization (IVNV), avascular/total retinal areas, and endothelial tip cell filopodial number and length were determined in lectin-labeled neurosensory retinal flat mounts. Cryosections or fresh tissue were analyzed for phospho-VEGFR1, phospho-VEGFR2, activated caspase-3, or phospho-beta3 integrin. Human umbilical venous (HUVECs) and human choroidal endothelial cells (ECs) were treated with VEGFR2 inhibitor to determine effect on VEGFR2 phosphorylation and on directed EC migration toward a VEGF gradient. Filopodial length and number of migrated ECs were also measured. Compared to control, the VEGFR2 inhibitor reduced VEGFR2 phosphorylation in HUVECs in vitro and clock hours and areas of IVNV but not percent avascular retina in vivo. Filopodial length and number of filopodia/EC tip cell were reduced in retinal flat mounts at doses that inhibited IVNV, whereas at lower doses, only a reduction in filopodial length/EC tip cell was found. There was no difference in phosphorylated beta3 integrin and cleaved caspase-3 labeling in VEGFR2 inhibitor-treated compared to control in vivo. Doses of the VEGFR2 inhibitor that reduced filopodial length and number of filopodia/migrating EC corresponded to reduced EC migration in in vitro models. VEGFR2 inhibitor reduced IVNV and filopodial number and length/EC tip cell without interfering with intraretinal vascularization. Reducing the number and length of filopodia/endothelial tip cell may reduce guidance cues for endothelial cells to migrate into the vitreous without interfering with migration into the retina toward a VEGF gradient.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19576214      PMCID: PMC2757474          DOI: 10.1016/j.exer.2009.06.011

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  45 in total

1.  Nonvascular role for VEGF: VEGFR-1, 2 activity is critical for neural retinal development.

Authors:  G S Robinson; M Ju; S C Shih; X Xu; G McMahon; R B Caldwell; L E Smith
Journal:  FASEB J       Date:  2001-05       Impact factor: 5.191

Review 2.  Role of vascular endothelial growth factor in regulation of physiological angiogenesis.

Authors:  N Ferrara
Journal:  Am J Physiol Cell Physiol       Date:  2001-06       Impact factor: 4.249

3.  Localization of VEGF receptor-2 (KDR/Flk-1) and effects of blocking it in oxygen-induced retinopathy.

Authors:  D Scott McLeod; Makoto Taomoto; Jingtai Cao; Zhenping Zhu; Larry Witte; Gerard A Lutty
Journal:  Invest Ophthalmol Vis Sci       Date:  2002-02       Impact factor: 4.799

4.  Disoriented pathfinding by pioneer neurone growth cones deprived of filopodia by cytochalasin treatment.

Authors:  D Bentley; A Toroian-Raymond
Journal:  Nature       Date:  1986 Oct 23-29       Impact factor: 49.962

5.  Indirect relation between rises in oxygen consumption and left ventricular output at birth in lambs.

Authors:  J J Smolich; M Soust; P J Berger; A M Walker
Journal:  Circ Res       Date:  1992-08       Impact factor: 17.367

6.  Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration.

Authors:  B Oosthuyse; L Moons; E Storkebaum; H Beck; D Nuyens; K Brusselmans; J Van Dorpe; P Hellings; M Gorselink; S Heymans; G Theilmeier; M Dewerchin; V Laudenbach; P Vermylen; H Raat; T Acker; V Vleminckx; L Van Den Bosch; N Cashman; H Fujisawa; M R Drost; R Sciot; F Bruyninckx; D J Hicklin; C Ince; P Gressens; F Lupu; K H Plate; W Robberecht; J M Herbert; D Collen; P Carmeliet
Journal:  Nat Genet       Date:  2001-06       Impact factor: 38.330

7.  Selective stimulation of VEGFR-1 prevents oxygen-induced retinal vascular degeneration in retinopathy of prematurity.

Authors:  Shu-Ching Shih; Meihua Ju; Nan Liu; Lois E H Smith
Journal:  J Clin Invest       Date:  2003-07       Impact factor: 14.808

8.  Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial.

Authors: 
Journal:  Arch Ophthalmol       Date:  2003-12

9.  Can changes in clinical practice decrease the incidence of severe retinopathy of prematurity in very low birth weight infants?

Authors:  Lily C Chow; Kenneth W Wright; Augusto Sola
Journal:  Pediatrics       Date:  2003-02       Impact factor: 7.124

10.  VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia.

Authors:  Holger Gerhardt; Matthew Golding; Marcus Fruttiger; Christiana Ruhrberg; Andrea Lundkvist; Alexandra Abramsson; Michael Jeltsch; Christopher Mitchell; Kari Alitalo; David Shima; Christer Betsholtz
Journal:  J Cell Biol       Date:  2003-06-16       Impact factor: 10.539

View more
  23 in total

1.  Increased angiogenic factors associated with peripheral avascular retina and intravitreous neovascularization: a model of retinopathy of prematurity.

Authors:  Steven J Budd; M Elizabeth Hartnett
Journal:  Arch Ophthalmol       Date:  2010-05

2.  VEGFA activates erythropoietin receptor and enhances VEGFR2-mediated pathological angiogenesis.

Authors:  Zhihong Yang; Haibo Wang; Yanchao Jiang; M Elizabeth Hartnett
Journal:  Am J Pathol       Date:  2014-03-12       Impact factor: 4.307

3.  Lutein facilitates physiological revascularization in a mouse model of retinopathy of prematurity.

Authors:  Zhongjie Fu; Steven S Meng; Samuel B Burnim; Lois Eh Smith; Amy Cy Lo
Journal:  Clin Exp Ophthalmol       Date:  2017-01-29       Impact factor: 4.207

4.  Breaking barriers: insight into the pathogenesis of neovascular age-related macular degeneration.

Authors:  Haibo Wang; Erika S Wittchen; M Elizabeth Hartnett
Journal:  Eye Brain       Date:  2011-09-27

5.  The role of RPE cell-associated VEGF₁₈₉ in choroidal endothelial cell transmigration across the RPE.

Authors:  Haibo Wang; Pete Geisen; Erika S Wittchen; Bradley King; Keith Burridge; Patricia A D'Amore; M Elizabeth Hartnett
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-02-01       Impact factor: 4.799

6.  Effect of VEGF trap on normal retinal vascular development and oxygen-induced retinopathy in the dog.

Authors:  Gerard A Lutty; D Scott McLeod; Imran Bhutto; Stanley J Wiegand
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-06-08       Impact factor: 4.799

Review 7.  Vascular endothelial growth factor antagonist therapy for retinopathy of prematurity.

Authors:  M Elizabeth Hartnett
Journal:  Clin Perinatol       Date:  2014-09-23       Impact factor: 3.430

8.  Disruption of the association of integrin-associated protein (IAP) with tyrosine phosphatase non-receptor type substrate-1 (SHPS)-1 inhibits pathophysiological changes in retinal endothelial function in a rat model of diabetes.

Authors:  L A Maile; K Gollahon; C Wai; G Byfield; M E Hartnett; D Clemmons
Journal:  Diabetologia       Date:  2011-12-23       Impact factor: 10.122

9.  Anti-VEGF antibody leads to later atypical intravitreous neovascularization and activation of angiogenic pathways in a rat model of retinopathy of prematurity.

Authors:  Manabu McCloskey; Haibo Wang; Yanchao Jiang; George Wesley Smith; Jeremy Strange; M Elizabeth Hartnett
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-03-21       Impact factor: 4.799

10.  Loss of MLK3 signaling impedes ulcer healing by modulating MAPK signaling in mouse intestinal mucosa.

Authors:  Pavlo L Kovalenko; Lyudmyla Kunovska; Jian Chen; Kathleen A Gallo; Marc D Basson
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-08-23       Impact factor: 4.052

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.